Predicting how well chemotherapy works before stomach surgery
Part of Cancer, Digestive system clinical trials.
This study looks for ways to predict whether neoadjuvant chemotherapy (chemo given before surgery) will work well in people with locally advanced stomach cancer. It may help doctors choose the best treatment plan sooner based on your test results.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old
- You have stomach cancer confirmed by biopsy during an endoscopy
- Your cancer is considered “resectable,” meaning surgery may be possible
- You are in overall good physical condition (ECOG 0–1) and can follow study visits
- Your blood counts and organ function are strong enough (blood tests and heart/liver/kidney markers meet limits)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses two types of PET/CT scans (FDG and FAPI) to see how well chemotherapy or other treatments work before surgery for stomach cancer that has spread to the lining of the abdomen. The goal is to find the best way to measure treatment response and help guide your care.
This trial tests a combination of an immunotherapy drug (sintilimab) and a low-dose weekly chemotherapy regimen before surgery for locally advanced stomach cancer that can be removed. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests whether a special PET/CT scan (using a drug called [18F]F-FAPI) and a laparoscopy (a small camera through the belly) can better show the spread of advanced stomach or esophagus cancer before surgery. The goal is to help doctors decide the best treatment plan.
This trial tests a combination of chemotherapy drugs given before surgery for locally advanced stomach or gastroesophageal junction cancer. It aims to see if this approach helps shrink the tumor and improve outcomes.
This trial is for people who have already had chemotherapy and surgery for stomach cancer. It compares different follow-up approaches to see if skipping more chemo after surgery is safe and effective.
This trial tests a combination of four chemotherapy drugs (irinotecan liposome, 5-FU + leucovorin, oxaliplatin, and Karelizumab) given before surgery to shrink stomach cancer. The goal is to see if this combination makes the cancer easier to remove and improves outcomes.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.